Imperial College London
Portrait Picture

ProfessorNagyHabib

Faculty of Medicine, Department of Surgery & Cancer

Professor of Hepatobiliary Surgery
 
 
 
//

Contact

 

+44 (0)20 3313 8574nagy.habib

 
 
//

Assistant

 

Mrs Benita White +44 (0)7960 986 387

 
//

Location

 

BN1/18 B BlockHammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Frilling:2019:10.1016/j.hpb.2018.12.014,
author = {Frilling, A and Clift, AK and Braat, AJAT and Alsafi, A and Wasan, HS and Al-Nahhas, A and Thomas, R and Drymousis, P and Habib, N and Tait, PN},
doi = {10.1016/j.hpb.2018.12.014},
journal = {HPB},
pages = {773--783},
title = {Radioembolisation with 90Y microspheres for neuroendocrine liver metastases: an institutional case series, systematic review and meta-analysis},
url = {http://dx.doi.org/10.1016/j.hpb.2018.12.014},
volume = {21},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: Neuroendocrine liver metastases are clinically challenging due to their frequent disseminated distribution. This study aims to present a British experience with an emerging modality, radioembolisation with yttrium-90 labelled microspheres, and embed this within a meta-analysis of response and survival outcomes. METHODS: A retrospective case series of patients treated with SIR-Spheres (radiolabelled resin microspheres) was performed. Results were included in a systematic review and meta-analysis of published results with glass or resin microspheres. Objective response rate (ORR) was defined as complete or partial response. Disease control rate (DCR) was defined as complete/partial response or stable disease. RESULTS: Twenty-four patients were identified. ORR and DCR in the institutional series was 14/24 and 21/24 at 3 months. Overall survival and progression-free survival at 3-years was 77.6% and 50.4%, respectively. There were no grade 3/4 toxicities post-procedure. A fixed-effects pooled estimate of ORR of 51% (95% CI: 47%-54%) was identified from meta-analysis of 27 studies. The fixed-effects weighted average DCR was 88% (95% CI: 85%-90%, 27 studies). CONCLUSION: Current data demonstrate evidence of the clinical effectiveness and safety of radioembolisation for neuroendocrine liver metastases. Prospective randomised studies to compare radioembolisation with other liver directed treatment modalities are needed.
AU  - Frilling,A
AU  - Clift,AK
AU  - Braat,AJAT
AU  - Alsafi,A
AU  - Wasan,HS
AU  - Al-Nahhas,A
AU  - Thomas,R
AU  - Drymousis,P
AU  - Habib,N
AU  - Tait,PN
DO  - 10.1016/j.hpb.2018.12.014
EP  - 783
PY  - 2019///
SN  - 1365-182X
SP  - 773
TI  - Radioembolisation with 90Y microspheres for neuroendocrine liver metastases: an institutional case series, systematic review and meta-analysis
T2  - HPB
UR  - http://dx.doi.org/10.1016/j.hpb.2018.12.014
UR  - https://www.ncbi.nlm.nih.gov/pubmed/30733049
UR  - http://hdl.handle.net/10044/1/66964
VL  - 21
ER  -
Download